Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 82, Issue 4 , Pages 219-225 , April 2010

Fatty acid oxidation and isoprostanes: Oxidative strain and oxidative stress

  • Samar Basu

      Affiliations

    • Oxidative Stress and Inflammation, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
    • Center of Excellence-Inflammation, Uppsala University Hospital, Uppsala, Sweden
    • Corresponding Author InformationCorresponding author at: Oxidative Stress and Inflammation, Department of Public Health and Caring Sciences, Faculty of Medicine, Uppsala University, Uppsala Science Park, SE-751 85 Uppsala, Sweden. Tel.: +46186117958; fax: +46186117976.

References 

  1. Droge W. Free radicals in the physiological control of cell function. Physiological Reviews. 2002;82:47–95
  2. Finkel T. Oxygen radicals and signaling. Current Opinion in Cell Biology. 1998;10:248–253
  3. Finkel T. Reactive oxygen species and signal transduction. IUBMB Life. 2001;52:3–6
  4. Finkel T. Oxidant signals and oxidative stress. Current Opinion in Cell Biology. 2003;15:247–254
  5. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxidant & Redox Signaling. 2008;10:1405–1434
  6. Bogdan C. Nitric oxide and the regulation of gene expression. Trends in Cell Biology. 2001;11:66–75
  7. Ishihara O, Hayashi M, Osawa H, et al. Isoprostanes, prostaglandins and tocopherols in pre-eclampsia, normal pregnancy and non-pregnancy. Free Radical Research. 2004;38:913–918
  8. Palm M, Axelsson O, Wernroth L, Basu S. F(2)-isoprostanes, tocopherols and normal pregnancy. Free Radical Research. 2009;43:546–552
  9. Helmersson J, Basu S. F2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 1999;61:203–205
  10. Helmersson J, Basu S. F(2)-isoprostane and prostaglandin F(2 alpha)metabolite excretion rate and day to day variation in healthy humans. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2001;65:99–102
  11. Basu S, Helmersson J. Factors regulating isoprostane formation in vivo. Antioxidants & Redox Signaling. 2005;7:221–235
  12. Basu S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F(2alpha) from physiology to new principles in inflammation. Medicinal Research Reviews. 2007;27:435–468
  13. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2005;73:141–162
  14. Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radical Research. 2004;38:105–122
  15. Basu S. The enigma of in vivo oxidative stress assessment: isoprostanes as an emerging target. Scandinavian Journal of Food and Nutrition. 2007;51:48–61
  16. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239–247
  17. Nemoto S, Finkel T. Ageing and the mystery at Arles. Nature. 2004;429:149–152
  18. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–790
  19. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. The New England Journal of Medicine. 2008;358:2107–2116
  20. In: H. Sies (Ed.), Oxidative Stress: Introductory Remarks, Academic Press, London, 1985, pp. 1–8.
  21. Morrow JD. The isoprostanes – unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Current Pharmaceutical Design. 2006;12:895–902
  22. Morrow JD, Roberts LJ. The isoprostanes. Current knowledge and directions for future research. Biochemical Pharmacology. 1996;51:1–9
  23. Montuschi P, Barnes P, Roberts LJ. Insights into oxidative stress: the isoprostanes. Current Medicinal Chemistry. 2007;14:703–717
  24. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of oxidative stress study. II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radical Biology & Medicine. 2005;38:698–710
  25. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of oxidative stress study. III: Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radical Biology & Medicine. 2005;38:711–718
  26. Nugteren DH, Vonkeman H, Van Dorf DA. Non-enzymatic conversion of all cis-8,11,14-eicosatrienoic acid into PGE1. Recueil des Travaux Chimiques des Pays-Bas. 1967;86:1237–1245
  27. Porter NA, Funk MO. Letter: peroxy radical cyclization as a model for prostaglandin biosynthesis. Journal of Organic Chemistry. 1975;40:3614–3615
  28. Morrow JD, Awad JA, Kato T, et al. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. The Journal of Clinical Investigation. 1992;90:2502–2507
  29. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America. 1990;87:9383–9387
  30. Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metabolism Reviews. 2000;32:377–385
  31. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radical Biology & Medicine. 2000;28:505–513
  32. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proceedings of the National Academy of Sciences of the United States of America. 1992;89:10721–10725
  33. Basu S. Metabolism of 8-iso-prostaglandin F2alpha. FEBS Letters. 1998;428:32–36
  34. Chiabrando C, Valagussa A, Rivalta C, et al. Identification and measurement of endogenous beta-oxidation metabolites of 8-epi-prostaglandin F2alpha. The Journal of Biological Chemistry. 1999;274:1313–1319
  35. Roberts LJ, Moore KP, Zackert WE, Oates JA, Morrow JD. Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans. The Journal of Biological Chemistry. 1996;271:20617–20620
  36. Basu S. Radioimmunoassay of 8-iso-prostaglandin F2alpha: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 1998;58:319–325
  37. Basu S, Riserus U, Turpeinen A, Vessby B. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clinical Science (London). 2000;99:511–516
  38. Richelle M, Turini ME, Guidoux R, Tavazzi I, Metairon S, Fay LB. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Letters. 1999;459:259–262
  39. Wang Z, Ciabattoni G, Creminon C, et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. The Journal of Pharmacology and Experimental Therapeutics. 1995;275:94–100
  40. Bachi A, Zuccato E, Baraldi M, Fanelli R, Chiabrando C. Measurement of urinary 8-epi-prostaglandin F2alpha, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and non-smokers. Free Radical Biology & Medicine. 1996;20:619–624
  41. Ide T, Tsutsui H, Ohashi N, et al. Greater oxidative stress in healthy young men compared with premenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:438–442
  42. Helmersson J, Mattsson P, Basu S. Prostaglandin F(2alpha) metabolite and F(2)-isoprostane excretion rates in migraine. Clinical Science (London). 2002;102:39–43
  43. Schraag S, Mandach U, Schweer H, Beinder E. Metabolic changes, hypothalamo–pituitary–adrenal axis and oxidative stress after short-term starvation in healthy pregnant women. Journal of Perinatal Medicine. 2007;35:289–294
  44. Gutteridge JM, Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends in Biochemical Sciences. 1990;15:129–135
  45. Basu S, Helmersson J. Bioactive isoprostanes. New markers of oxidative stress and inflammation-related diseases. Lakartidningen. 2009;106:274–278
  46. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. The Journal of Biological Chemistry. 1999;274:24441–24444
  47. Basu S. Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity. Biochemical and Biophysical Research Communications. 1999;254:764–767
  48. Sodergren E, Cederberg J, Vessby B, Basu S. Vitamin E reduces lipid peroxidation in experimental hepatotoxicity in rats. European Journal of Nutrition. 2001;40:10–16
  49. Gopaul NK, Halliwell B, Anggard EE. Measurement of plasma F2-isoprostanes as an index of lipid peroxidation does not appear to be confounded by diet. Free Radical Research. 2000;33:115–127
  50. H. Petersson, U. Risérus, J. McMonagle, A.C. Tierney, J. Lovegrave, S. Morange, O. Helal, H.L. Gulseth, J.A. Ruano, J. Lopez-Miranda, A. Dembinska-Kiec, E. Blaak, I.M.F. Gjeldstad, C.A. Drevon, H. Roche, S. Basu, Effects of dietary fat modification on oxidative stress and inflammatory markers in the LIPGENE study, British Journal of Nutrition (2009), under review.
  51. Sodergren E, Cederberg J, Basu S, Vessby B. Vitamin E supplementation decreases basal levels of F(2)-isoprostanes and prostaglandin F(2alpha) in rats. The Journal of Nutrition. 1999;130:10–14
  52. Sodergren E, Vessby B, Basu S. Radioimmunological measurement of F(2)-isoprostanes after hydrolysis of lipids in tissues. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2000;63:149–152
  53. DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology. 1997;49:S15–S19
  54. Basu S, Larsson A, Vessby J, Vessby B, Berne C. Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care. 2005;28:1371–1375
  55. Helmersson J, Larsson A, Vessby B, Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis. 2005;181:201–207
  56. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation. 2004;109:1729–1734
  57. Sinaiko AR, Steinberger J, Moran A, et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation. 2005;111:1985–1991
  58. Wohlin M, Helmersson J, Sundstrom J, et al. Both cyclooxygenase- and cytokine-mediated inflammation are associated with carotid intima-media thickness. Cytokine. 2007;38:130–136
  59. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association task force on risk reduction. Circulation. 1997;96:3243–3247
  60. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. The New England Journal of Medicine. 1995;332:1198–1203
  61. Ahmadzadehfar H, Oguogho A, Efthimiou Y, Kritz H, Sinzinger H. Passive cigarette smoking increases isoprostane formation. Life Sciences. 2006;78:894–897
  62. Basu S, Helmersson J, Jarosinska D, Sallsten G, Mazzolai B, Barregard L. Regulatory factors of basal F(2)-isoprostane formation: population, age, gender and smoking habits in humans. Free Radical Research. 2009;43:85–91
  63. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999;99:224–229
  64. Davi G, Chiarelli F, Santilli F, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation. 2003;107:3199–3203
  65. Gleisner A, Martinez L, Pino R, et al. Oxidative stress markers in plasma and urine of prepubertal patients with type 1 diabetes mellitus. Journal of Pediatric Endocrinology & Metabolism. 2006;19:995–1000
  66. Hoeldtke RD, Bryner KD, McNeill DR, Warehime SS, Van Dyke K, Hobbs G. Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2003;88:1624–1628
  67. O'Byrne S, Forte P, Roberts LJ, et al. Nitric oxide synthesis and isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion. Diabetes. 2000;49:857–862
  68. Vessby J, Basu S, Mohsen R, Berne C, Vessby B. Oxidative stress and antioxidant status in type 1 diabetes mellitus. Journal of Internal Medicine. 2002;251:69–76
  69. Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Letters. 1995;368:225–229
  70. Gopaul NK, Manraj MD, Hebe A, et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia. 2001;44:706–712
  71. Murai Y, Hishinuma T, Suzuki N, Satoh J, Toyota T, Mizugaki M. Determination of urinary 8-epi-prostaglandin F(2alpha) using liquid chromatography-tandem mass spectrometry: increased excretion in diabetics. Prostaglandins & Other Lipid Mediators. 2000;62:173–181
  72. Davi G, Di Minno G, Coppola A, et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation. 2001;104:1124–1128
  73. Cracowski JL, Baguet JP, Ormezzano O, et al. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension. 2003;41:286–288
  74. Minuz P, Patrignani P, Gaino S, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation. 2002;106:2800–2805
  75. Lopes HF, Martin KL, Nashar K, Morrow JD, Goodfriend TL, Egan BM. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. Hypertension. 2003;41:422–430
  76. Ward NC, Hodgson JM, Puddey IB, Mori TA, Beilin LJ, Croft KD. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radical Biology & Medicine. 2004;36:226–232
  77. Cracowski JL, Cracowski C, Bessard G, et al. Increased lipid peroxidation in patients with pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine. 2001;164:1038–1042
  78. Urakawa H, Katsuki A, Sumida Y, et al. Oxidative stress is associated with adiposity and insulin resistance in men. The Journal of Clinical Endocrinology and Metabolism. 2003;88:4673–4676
  79. K.M. Pou, J.M. Massaro, U. Hoffmann, et al., Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. The Framingham heart study, Circulation (2007).
  80. Davi G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. Journal of the American Medical Association. 2002;288:2008–2014

PII: S0952-3278(10)00075-X

doi: 10.1016/j.plefa.2010.02.031

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 82, Issue 4 , Pages 219-225 , April 2010

Article Tools

* Image Usage & Resolution